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Background: Intrahepatic recurrence after resection of intrahepatic or hilar cholangiocarcinoma repre-
sents a main reason for the poor prognosis of bile duct cancer. As no standard treatment has been
established so far, the aim of this study was to analyse the safety and efficacy of computed tomography-
guided high-dose rate brachytherapy (CT-HDRBT) as an alternative treatment in those patients.
Methods: The outcomes of 10 patients, who had been treated at least once for recurrent cholangiocar-
cinoma by CT-HDRBT, were retrospectively analysed.
Results: The median survival of all patients after primary liver resection was 85 months [95% confidence
interval (CI) 68.129-101.871] with overall 1- and 5-year survival rates of 100% and 78.7%, respectively.
After the occurrence of intrahepatic tumour recurrence, a total of 15 CT-HDRBT procedures were
performed, alone or combined with other recurrence treatments, without any major complications accord-
ing to the Society of Interventional Radiology classification. The 1-year and 5-year survival rates after
recurrence treatment were 77.1% and 51.4%, respectively.
Conclusions: CT-HDRBT represents a safe treatment option for patients with recurrent bile duct cancer.
As a part of a multimodal concept, CT-HDRBT might lead to a prolongation of survival in selected patients
but further studies are urgently needed to prove this concept.
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Introduction
Bile duct cancer is a rare type of cancer; however, its worldwide
incidence has increased in recent years.1–3 Approximately 3% of
all gastrointestinal cancers in the Western world arise from the
epithelial cells of the bile duct4,5 and can be classified into intra-
hepatic, hilar or distal cholangiocarcinomas based on tumour
location.6 As a result of the early wide spread of the disease and
rapid tumour growth, the prognosis of bile duct tumours
remains poor. In spite of advances in chemotherapeutic con-
cepts, surgery is the only curative treatment option for these
patients, and survival rates are often unsatisfactory. Even after
curative resection, 5-year survival rates rarely exceed 40% for
intrahepatic7 or hilar cholangiocarcinoma8 and 50% for distal
bile duct cancers.9 Liver resection is the standard treatment for
intrahepatic and hilar cholangiocarcinomas, whereas a pancre-
aticoduodenectomy must be performed to treat distal bile duct
tumours. Recent studies show that recurrence rates are often
high after curative liver resection for intrahepatic and hilar cho-
langiocarcinomas, with the liver being the most frequent site
of tumour recurrence.10–12 No standard treatment has been
established for patients with intrahepatic recurrence of bile duct
cancer. Several chemotherapeutic agents, including gemcitabine
and cisplatin, could provide a minor benefit to these patients,
but the prognosis remains poor.13 Solitary or combined repeated
liver resection and radiofrequency ablation (RFA) for the
treatment of recurrent cholangiocarcinoma has been described
in smaller series and might lead to prolongation of
survival,12,14 but large prospective studies are required to prove
this concept.
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Since 2002, the technique of computed tomography-guided
high-dose rate brachytherapy (CT-HDRBT) has been used for the
treatment of different hepatic malignancies, and promising results
have been presented, especially in colorectal cancer metastases15
and hepatocellular carcinoma.16 In a recently published series, we
showed that CT-HDRBT may be a promising and safe treatment
option for patients with unresectable intrahepatic cholangiocar-
cinoma.17 However, to the best of our knowledge, no study has
evaluated the outcome of patients undergoing CT-HDRBT for the
treatment of hepatic recurrence of bile duct cancer.
The aim of this study was to analyse the feasibility and efficacy
of CT-HDRBT as an alternative treatment for patients with
hepatic recurrence after primary liver resection because of intra-
hepatic or hilar cholangiocarcinoma.
Material and methods
Between April 2002 and August 2008, a total of 265 patients
underwent liver resection because of intrahepatic or hilar cholan-
giocarcinoma at our centre. In case of recurrent disease (about
65% of the entire cohort) chemotherapy was offered to all patients
as standard treatment. A repeated liver resection or alternative
procedures such as radiofrequency ablation or photodynamic
therapy were performed in selected individual cases as part of
small studies. Ten patients developed recurrent intrahepatic
tumours that were regarded as non-resectable but suitable for
CT-HDRBT as part of this feasibility study. Non-resectability of
recurrent tumours was determined by institutional surgeons, and
the indication for local tumour ablation was confirmed by an
interdisciplinary tumour board. Data of all patients eligible for the
study were obtained from a prospectively collected database.
Patients were excluded in cases of incomplete medical files or if
another malignancy occurred during the follow-up period. All
patients provided written informed consent prior to the study
after receiving an explanation of the rationale of the study.
For all patients included in the study, the following data were
collected: demographics, primary tumour location, primary liver
resection, details of intrahepatic tumour recurrence, details of
CT-HDRBT procedures and follow-up including survival.
Contraindications for local brachytherapy included total biliru-
bin > 2.5 mg/dl (after internal biliary drainage if severe cholestasis
was present); multiple, disseminated liver lesions (n > 5); or
uncorrectable, impaired coagulation and massive ascites.
Liver MRI with a hepatocyte-specific contrast agent (Gd-EOB,
Primovist, BayerSchering Pharma, Leverkusen, Germany) was
performed 1 day before CT-HDRBT to assess technical feasibility.
Sedation with midazolam and fentanyl and local anaesthesia
(lidocaine) was administered intravenously. Subsequently, under
CT-fluoroscopy, a direct percutaneous transhepatic puncture of
the parenchymal tumours was performed with a 17-G needle
(KCS Martin, Umkirch, Germany) and 6-F angiographic sheaths
(Terumo, Tokyo, Japan) were inserted according to Seldinger’s
technique using an 0.035” guiding wire (Amplatz Super Stiff,
Boston Scientific, Natick, MA, USA). Through these sheaths, the
closed-ended 6-F afterloading catheters were introduced.
Contrast-enhanced CT data sets with the catheters in situ were
used for 3D radiation planning (Brachyvision, Varian Medical
Systems, Palo Alto, CA, USA), which was performed by a radiolo-
gist and a radiation oncologist in consensus. The clinical target
volume (CTV) was defined as the visible tumour borders, includ-
ing the enhancing rim, on contrast-enhanced CT scans. Catheters,
CTV and potential risk structures were manually registered. Next,
semiautomatic calculation of the brachytherapy plan was per-
formed; this involved calculation of dwell times and dwell loca-
tions of an iridium-192 source (Gammamed, Varian Medical
Systems, Palo Alto, CA, USA) inside the catheters to cover the CTV
with the intended minimal dose. The desired CTV-enclosing dose
was 20 Gray (Gy), but it was reduced in certain cases where adja-
cent structures were at risk. During retraction of the catheters
after completion of the brachytherapy procedure, the puncture
channels were sealed with resorbable, thrombogenic material
(Gelfoam, Pfizer Inc., New York, NY, USA) to avoid bleeding.
The routine follow-up consisted of clinical visits and liver MRI
with Gd-EOB at 6, 12 weeks and then every third month after
therapy completion (CT of the chest every sixth month). Patients
with local tumour progression who were eligible for repetitive
local ablation underwent repetitive brachytherapy. Local control
rates, time to progression, patient survival, complications [accord-
ing to the Society of Interventional Radiology (SIR) classification]
and additional therapies were documented.
Statistical analysis was performed using the SPSS 19.0 statistical
software (SPSS, Chicago, IL, USA). Quantitative values were
expressed as median and range. Overall survival was estimated
using the Kaplan–Meier method. As a result of the small sample
size, no further statistical tests were regarded as useful.
Results
Demographics and primary procedure
This study consisted of five male (50%) and five female (50%)
patients with a median age of 64 years (range, 49–80 years). Six of
these 10 patients (60%), all of whom underwent liver resection at
our centre, had an intrahepatic cholangiocarcinoma, whereas 4
patients (40%) had hilar cholangiocarcinoma.
Operative procedures included extended liver resection in nine
patients and a wedge resection in one patient. One patient under-
went additional intra-operative RFA of a distant liver tumour
manifestation.
Histopathological examination confirmed the diagnosis of
intrahepatic or hilar cholangiocarcinoma in all cases. Most
tumours were classified as T3 (70%), whereas a positive lymph
node status (N1) was detected in 6 patients (60%). An R0 resec-
tion of the tumour could be achieved in six patients (60%),
whereas the tumour had reached the hepatic resection margin
(R1) in four cases (40%). Distant metastases were not found in
any of the patients.
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A detailed summary of patient demographics as well as details
of primary liver resection and recurrence treatment is depicted in
Table 1.
Tumour recurrence
All patients developed intrahepatic, parenchymal tumour recur-
rence after a median time of 19 months (range, 2–59). Six patients
underwent CT-HDRBT as a treatment for first tumour recur-
rence, whereas RFA was performed in two patients. One patient
was treated by photodynamic therapy, whereas a repeated liver
resection was performed for another patient.
After another median period of 8 months (range, 5–30), a
second tumour recurrence was detected and regarded as treatable
in six patients. Five of these patients underwent CT-HDRBT,
whereas one patient underwent wedge resection for intrahepatic
tumour recurrence. During additional follow-up, CT-HDRBT
was repeatedly performed as a third tumour recurrence treatment
in three patients, whereas one patient underwent a total of four
procedures (RFA, wedge resection, and 2 ¥ CT-HDRBT) as a
result of recurrent disease.
CT-HDRBT
All CT-HDRBT treatments were performed without major com-
plications according to the SIR classification. The median amount
of lesions was 1, 2 patients had two sites of tumour recurrence and
1 patient 3 lesions. The mean size was 31 14 mm (range, 11–54)
and the resulting clinical target volume of the radiated tumours
was 23 25 ml (range, 4–85) with a median tumour surrounding
target dose of 20 Gy. For 1 patient, the dose had to be reduced to
17 Gy and in 2 patients to 15 Gy because the stomach was adjacent
to the tumour or because of a bilirubin of 1.7 mg/dl. Altogether,
15 CT-HDRBT treatments were performed for 6 patients who had
1 treatment, 3 patients with 2 treatments, and 1 patient with 3
CT-HDRBT sessions (Fig. 1). The median amount of catheters
used was 2 (range, 1–3).
Patient survival
After a median follow-up of 46 months (range, 12–105) after
primary liver resection, 6 of the 10 patients are still alive. All
of them have local tumour control and have not received addi-
tional chemotherapy after the last CT-HDRBT treatment. All
four patients who died had developed multifocal untreatable
tumour recurrence and had undergone short-term palliative
chemotherapy.
The median survival of all patients after primary liver resection
was 85 months [95% confidence interval (CI), 68.129–101.871).
The overall 1- and 5-year survival rates of the entire cohort were
100% and 78.7%, respectively (Fig. 2).
After the occurrence of intrahepatic tumour recurrence, the
overall 1- and 5-year survival rates of the entire cohort were 77.1%
and 51.4%, respectively (Fig. 3). Detailed information concerning
follow-up and survival times are depicted in Table 1.
Discussion
Surgery is widely accepted to be the only curative treatment
option for intra- and extrahepatic cholangiocarcinomas; however,
even after curative resection, the prognosis of these patients often
remains poor.1–7 One reason for this poor prognosis is the high
rate of tumour recurrence, which is reported to be up to 70% in
recent studies.10,14,18 In spite of great efforts, no standard treatment
has been established for intrahepatic tumour recurrence of bile
duct cancer. Recently published results of the ABC-02 trial show
that chemotherapy, including gemcitabine and cisplatin, is an
Table 1 Clinical features of 10 patients who underwent CT-HDRBT for intrahepatic recurrence of intrahepatic or hilar cholangiocarcinoma
Pt Age
(years),
gender
Primary
surgical
procedure
IHC/
EHC
T N L R G 1st tumour
recurrence
(months after
the primary
procedure)
Treat-
ment
2nd tumour
recurrence
(months after
the primary
procedure)
Treat-
ment
3rd tumour
recurrence
(months after
the primary
procedure)
Treat-ment 4th tumour
recurrence
(months after
the primary
procedure)
Treat-
ment
Outcome
after
primary
procedure
1 80, F WR I 3 1 1 0 2 48 BT 55 BT 73 BT Alive, 105 months
2 63, M ERH I 4 0 0 0 2 59 BT 67 BT Dead, 74 months
3 54, F ELH E 3 0 1 0 3 57 BT Dead, 85 months
4 64, F ERH+RFA I 3 1 1 1 2 50 WR 70 BT 74 BT Alive, 83 months
5 73, M ELH I 3 0 0 0 3 13 BT Dead, 22 months
6 68, M ERH I 2 0 0 1 3 3 RFA 11 WR 15 BT 27 BT Alive, 45 months
7 49, M ERH E 3 1 1 1 2 2 PDT 32 BT Alive, 46 months
8 62, F ERH E 3 1 1 1 2 11 BT Dead, 12 months
9 75, F ELH E 1 0 0 0 2 18 BT Alive, 20 months
10 56, M LH I 3 0 0 0 2 20 RFA 25 Alive, 27 months
Pt, patient; CT-HDRBT, computed tomography-guided high-dose rate brachytherapy; F, female; M, male; pat, patient; LR, liver resection; RH, right
hepatectomy; LH, left hepatectomy; WR, wedge resection; ERH, extended right hepatectomy; ELH, extended left hepatectomy; IHC, intrahepatic
cholangiocarcinoma; EHC, extrahepatic/hilar cholangiocarcinoma; T, tumour stage; N, lymph node classification; L, lymphangiosis carcinomatosa; G,
grading; RFA, radiofrequency ablation; BT, brachytherapy.
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option in the palliative setting;13 however, chemotherapy is often
limited as a result of the patient’s performance status. Similarly,
repeated liver resection can only be performed in a few selected
patients with recurrent bile duct cancer. For these patients,
repeated liver resection might be a promising treatment
option.12,14,19 In our own centre, we demonstrated that repeated
liver resection is feasible with a low complication rate and a rel-
evant survival benefit.12 However, limitations such as bad perfor-
mance status, large tumour size and unfavourable tumour
location often do not allow any further surgical treatment, and
patients with these limitations require less invasive treatment
options. As a result of the promising results of RFA for the
treatment of solid liver malignancies in the past decade,20–22
several studies have already focused on the therapeutic effect of
RFA on hepatic recurrence of bile duct cancer.23,24 In a study by
Kim et al., a median survival of 27.4 months could be achieved in
29 patients with recurrent intrahepatic cholangiocarcinomas
treated by RFA.23 Although this study, as well as the present study,
is limited by small sample size, RFA might also play a beneficial
role in the treatment of patients with bile duct cancer recurrence.
However, major complications, such as liver abscesses or bile duct
strictures, occurred in 6.8%. These complications suggest that the
ablation technique requires further improvement and that RFA
has potential limitations.
CT-HDRBT is another minimally invasive procedure that has
become an established treatment option for solid liver tumours in
recent years. In contrast to RFA, CT-HDRBT is not limited to
tumours smaller than 5 cm and may be used for the treatment of
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 1 A 82-year-old patient who had undergone wedge resection of segment 4b (arrow, a) developed after 48 months intrahepatic
recurrence (*) of an intrahepatic cholangiocarcinoma in liver segment 7 (b), which was treated using computed tomography-guided
high-dose rate brachytherapy (CT-HDRBT) as a result of medical infirmity for an hepatic resection with a tumour surrounding target dose of
20 Gy (c). Seven months after first ablation the patient developed local recurrence (*) at the margin of the ablation zone (x) (d, e) which was
again treated by CT-HDRBT (f). A third ablation was performed 18 months later (not shown) with the same technique; 6 years after first
ablation the patient is still in local tumour control with no residual tumourous activity but typical function loss (x) of hepatocytes visible by
reduced Gd-EOB uptake at the site of the ablations (g–i)
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tumours near vital structures, such as blood vessels or the liver
hilum. Another advantage of the CT-HDRBT is its independence
from cooling effects of blood vessels or strong tumour perfusion.
However, as with all local ablative procedures, the use of
CT-HDRBT is limited to a small number of lesions and cannot be
performed in multilocular disease.
Two prospective trials have compared the effects of multiple
CT-HDRBT treatments with those of control treatments. Mohnike
et al. investigated patients with hepatocellucar carcinoma in a
matched pair analysis.16 In 55 pairs, the median survival of patients
undergoing CT-HDRBT was 37.5 months compared with
18 months for those receiving the best supportive care. Ricke et al.
investigated different dose levels with local control as the primary
endpoint (survival, secondary endpoint) in patients with meta-
static colorectal cancer in the liver;15 they found survival to be
highest in patients undergoing multiple CT-HDRBTs for evolving
new metastases at any location,with a larger benefit than additional
chemotherapy in a selected salvage population.
The beneficial effect of CT-HDRBT on intrahepatic cholang-
iocarcinoma was also presented in a recently published study.17
However, to the best of our knowledge, no study has evaluated
the safety and efficacy of CT-guided brachytherapy for recurrent
bile duct cancer. In the present study, a total of 15 CT-HDRBT
treatments were performed for 10 patients without major com-
plications; this highlights the safety of CT-HDRBT for the treat-
ment of patients with tumour recurrence after primary liver
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Figure 2 Overall survival curve [including 95% confidence interval (CI)] after primary liver resection of the entire cohort of 10 patients with
recurrent bile duct cancer
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Figure 3 Survival curve [including 95% confidence interval (CI)] of the entire cohort after treatment of first tumour recurrence
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resection. Moreover, the present study shows that long-term sur-
vival is possible in patients with recurrent cholangiocarcinoma.
Only two patients in our study cohort died within 1 year after
tumour recurrence, whereas survival times of more than
40 months could be achieved for other patients. The 5-year sur-
vival rate of the entire cohort after a primary liver resection was
78.7%, which is superior to that reported in most representative
studies, in spite of a recurrence rate of 100% and a R0-resection
rate of only 60% in the study cohort. However, this result might
be biased by a late time point of tumour recurrence in most of
the patients, as only 30% of the patients in the present study had
tumour recurrence within the first year after a primary liver
resection. Furthermore, 7 out of 10 patients had singular tumour
recurrence and none of the patients in this study showed more
than three recurrent lesions which underlines the fact that
tumour recurrence was detected in all patients in an early stage of
the disease. Nevertheless, even after the occurrence of intrahe-
patic tumour recurrence, a 5-year-survival rate of 51.4% could
be achieved for these patients; this highlights the fact that
CT-HDRBT might represent a promising option for selected
patients in a multidisciplinary treatment concept of patients with
recurrent cholangiocarcinoma. Although this study is limited by
its small sample size and a selection bias, it provides a promising
impression of the safety and efficacy of CT-HDRBT for patients
with a lack of treatment options and highlights the need for
further studies in this field.
Conclusion
The results of this feasibility study show that CT-HDRBT is a safe
treatment option for patients with hepatic recurrence after liver
resection for intra- and extrahepatic bile duct cancer. As part of a
multidisciplinary treatment concept, CT-HDRBT might prolong
survival in this selected group of patients. Further large prospec-
tive studies are required to prove this concept and to eventually
establish CT-HDRBT as a useful alternative treatment for bile
duct cancer in the palliative setting.
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